SkyCell, the purpose-led technology company transforming the pharmaceutical supply chain, has partnered with lane risk assessment platform, Validaide to improve decision-making and enhance lane risk assessments for pharmaceutical companies.
The pharmaceutical industry loses approximately $35 billion annually due to failures in temperature-controlled logistics. The partnership aims to address these challenges by allowing companies to make data-driven routing decisions, streamline lane risk assessments, and accelerate lane approvals for critical shipments, ultimately helping pharmaceutical companies make better supply chain decisions.
The partnership will see SkyMind — SkyCell’s supply chain software platform — integrate with Validaide’s lane risk assessment and ground handling data, allowing pharma companies to make better decisions based on risk, cost and carbon emissions. SkyMind’s CO₂e software DECARBONIZE is based on the Massachusetts Institute of Technology (MIT) latest research and methodology. The DECARBONIZE software allows the comparison of one-way versus reusable packaging options, allowing companies to minimize their environmental impact while making informed decisions. With this collaboration, Validaide’s platform will be enhanced to make lane risk assessments and CO₂e comparison with different packaging at the same time.
Earlier this year, SkyCell launched SkyMind an AI-powered learning system to enhance operational control and save costs by streamlining processes, maximizing efficiency, minimising unnecessary expenses and reducing CO₂ emissions. Validaide’s network includes over 1,300 companies, contributing data to its global platform for healthcare and pharma shipments. This extensive quantitative operational data, encompassing logistics suppliers’ handling capabilities, complements SkyMind’s qualitative operational data — enhancing decision-making for pharmaceutical companies during shipments.
Richard Ettl, co-founder and CEO of SkyCell: “SkyCell’s vision for pharma has always been zero loss and zero CO₂ emissions for the pharma supply chain. Technology is crucial for decision-makers to reduce costs, risks, and CO₂ emissions in pharma supply chains. Collaboration among stakeholders and technology providers is equally important. Our partnership with Validaide is a significant step forward, empowering pharmaceutical companies to take greater control of their supply chains.”
READ: LUFTHANSA CARGO ADDS NEW DESTINATIONS IN CHINA
Eelco De Jong, co-founder and managing director of Validaide said: “Our longstanding relationship with SkyCell has been marked by shared goals. This next step in our journey together will allow us to combine our qualitative operational data with SkyMind’s quantitative data — creating a comprehensive solution for the pharma industry. Together, we look forward to helping our customers make better, more informed supply chain decisions.”
